Spatial Mesh-Based Surface Source Model for the Electron Contamination of an 18 MV Photon Beams

Background

Source modeling is an approach to reduce computational burden in Monte Carlo simulations but at the cost of reduced accuracy. Although this method can be effective, one component of the source model that is exceptionally difficult to model is the electron contamination, a significant contributor to the skin and shallow dose.

Aims and Objectives

To improve the accuracy for the electron contamination component of the overall source model, we have generated a spatial mesh based surface source model.

Methods and Materials

The source model is located downstream from the flattening filter and mirror but upstream from the movable jaws. A typical phase space file uses around ten parameters per particle, but this method simplifies this number to five components. By using only the electron distance from the central axis, angles from the central axis and energy, the computational time and disk space required is greatly reduced.

Results and Conclusion

Despite the simplification in the source model, the electron contamination is still accurate to within 1.5%.

Stealthy Secret Key Generation

In order to make a warden, Willie, unaware of the existence of meaningful communications, there have been different schemes proposed including covert and stealth communications. When legitimate users have no channel advantage over Willie, the legitimate users may need additional secret keys to confuse Willie, if the stealth or covert communication is still possible. However, secret key generation (SKG) may raise Willie’s attention since it has a public discussion, which is observable by Willie. To prevent Willie’s attention, we consider the source model for SKG under a strong secrecy constraint, which has further to fulfill a stealth constraint. Our first contribution is that, if the stochastic dependence between the observations at Alice and Bob fulfills the strict more capable criterion with respect to the stochastic dependence between the observations at Alice and Willie or between Bob and Willie, then a positive stealthy secret key rate is identical to the one without the stealth constraint. Our second contribution is that, if the random variables observed at Alice, Bob, and Willie induced by the common random source form a Markov chain, then the key capacity of the source model SKG with the strong secrecy constraint and the stealth constraint is equal to the key capacity with the strong secrecy constraint, but without the stealth constraint. For the case of fast fading models, a sufficient condition for the existence of an equivalent model, which is degraded, is provided, based on stochastic orders. Furthermore, we present an example to illustrate our results.

An Integrated Framework Based on Full Monte Carlo Simulations for Double-Scattering Proton Therapy

PURPOSE

We developed an integrated framework that employs a full Monte Carlo (MC) model for treatment-plan simulations of a passive double-scattering proton system.

MATERIALS AND METHODS

We have previously validated a virtual machine source model for full MC proton-dose calculations by comparing the percentage of depth-dose curves, spread-out Bragg peaks, and lateral profiles against measured commissioning data. This study further expanded our previous work by developing an integrate framework that facilitates its clinical use. Specifically, we have (1) constructed patient-specific applicator and compensator numerically from the plan data and incorporated them into the beamline, (2) created the patient anatomy from the computed tomography image and established the transformation between patient and machine coordinate systems, and (3) developed a graphical user interface to ease the whole process from importing the treatment plan in the Digital Imaging and Communications in Medicine format to parallelization of the MC calculations. End-to-end tests were performed to validate the functionality, and 3 clinical cases were used to demonstrate clinical utility of the framework.

RESULTS

The end-to-end tests demonstrated that the framework functioned correctly for all tested functionality. Comparisons between the treatment planning system calculations and MC results in 3 clinical cases revealed large dose difference up to 17%, especially in the beam penumbra and near the end of beam range. The discrepancy likely originates from a variety of sources, such as the dose algorithms, modeling of the beamline, and the dose metric. The agreement for other regions was acceptable.

CONCLUSION

An integrated framework was developed for full MC simulations of double-scattering proton therapy. It can be a valuable tool for dose verification and plan evaluation.

Technical Note: An approach to building a Monte Carlo simulation model for a double scattering proton beam system

PURPOSE

The purpose of this study was to demonstrate and develop a Monte Carlo (MC) simulation model for a passive double scattering compact proton therapy system based on limited information of the mechanical components.

METHOD

We built a virtual machine source model (VMSM) which included a detailed definition of each beam-modifying component in the nozzle. Conceptually, it is similar to the conventional virtual analytical source model (VASM), except that the numerical machine nozzle or beamline is constructed in the VMSM, whereas in the VASM analytical parameters characterizing the energy spectrum and source fluence distribution are sought. All major beam shaping components were included in the VMSM and the model simulates interactions of the beam with a rotating range modulation wheel (RMW) combined with the beam current modulation. The RMWs, the first and second scatterer in the system were generated and tuned to reproduce measurement data as closely as possible. To validate the model, we compared the percent depth dose curves, spread out Bragg peaks (SOBPs) and lateral profiles against measured commissioning beam data.

RESULTS

The agreement of beam range between the MC calculation and measurement was within 1 mm for all beam options. The distal-falloff length was in good agreement as well (<1 mm for the large and deep groups, <1.5 mm for the small group). Agreement to within 2.5 mm of measured SOBP widths was obtained for all MC calculations. For lateral profiles, differences were found to be less than 2 mm.

CONCLUSIONS

We demonstrated that with limited geometrical information it is possible to build an acceptable source model for MC simulations of a passive double scattering compact proton therapy system. The agreement between the measurements and the MC model provides validation for use of the model for further studies of the dosimetric effects in patient treatments.

Development of a flattening filter free multiple source model for use as an independent, Monte Carlo, dose calculation, quality assurance tool for clinical trials

PURPOSE

The Imaging and Radiation Oncology Core-Houston (IROC-H) Quality Assurance Center (formerly the Radiological Physics Center) has reported varying levels of compliance from their anthropomorphic phantom auditing program. IROC-H studies have suggested that one source of disagreement between institution submitted calculated doses and measurement is the accuracy of the institution's treatment planning system dose calculations and heterogeneity corrections used. In order to audit this step of the radiation therapy treatment process, an independent dose calculation tool is needed.

METHODS

Monte Carlo multiple source models for Varian flattening filter free (FFF) 6 MV and FFF 10 MV therapeutic x-ray beams were commissioned based on central axis depth dose data from a 10 × 10 cm² field size and dose profiles for a 40 × 40 cm² field size. The models were validated against open-field measurements in a water tank for field sizes ranging from 3 × 3 cm² to 40 × 40 cm² . The models were then benchmarked against IROC-H's anthropomorphic head and neck phantom and lung phantom measurements.

RESULTS

Validation results, assessed with a ±2%/2 mm gamma criterion, showed average agreement of 99.9% and 99.0% for central axis depth dose data for FFF 6 MV and FFF 10 MV models, respectively. Dose profile agreement using the same evaluation technique averaged 97.8% and 97.9% for the respective models. Phantom benchmarking comparisons were evaluated with a ±3%/2 mm gamma criterion, and agreement averaged 90.1% and 90.8% for the respective models.

CONCLUSIONS

Multiple source models for Varian FFF 6 MV and FFF 10 MV beams have been developed, validated, and benchmarked for inclusion in an independent dose calculation quality assurance tool for use in clinical trial audits.

Development of a Monte Carlo multiple source model for inclusion in a dose calculation auditing tool

PURPOSE

The Imaging and Radiation Oncology Core Houston (IROC-H) (formerly the Radiological Physics Center) has reported varying levels of agreement in their anthropomorphic phantom audits. There is reason to believe one source of error in this observed disagreement is the accuracy of the dose calculation algorithms and heterogeneity corrections used. To audit this component of the radiotherapy treatment process, an independent dose calculation tool is needed.

METHODS

Monte Carlo multiple source models for Elekta 6 MV and 10 MV therapeutic x-ray beams were commissioned based on measurement of central axis depth dose data for a 10 × 10 cm² field size and dose profiles for a 40 × 40 cm² field size. The models were validated against open field measurements consisting of depth dose data and dose profiles for field sizes ranging from 3 × 3 cm² to 30 × 30 cm² . The models were then benchmarked against measurements in IROC-H's anthropomorphic head and neck and lung phantoms.

RESULTS

Validation results showed 97.9% and 96.8% of depth dose data passed a ±2% Van Dyk criterion for 6 MV and 10 MV models respectively. Dose profile comparisons showed an average agreement using a ±2%/2 mm criterion of 98.0% and 99.0% for 6 MV and 10 MV models respectively. Phantom plan comparisons were evaluated using ±3%/2 mm gamma criterion, and averaged passing rates between Monte Carlo and measurements were 87.4% and 89.9% for 6 MV and 10 MV models respectively.

CONCLUSIONS

Accurate multiple source models for Elekta 6 MV and 10 MV x-ray beams have been developed for inclusion in an independent dose calculation tool for use in clinical trial audits.

A Monte Carlo model and its commissioning for the Leksell Gamma Knife Perfexion radiosurgery system

PURPOSE

To develop and commission a Monte Carlo (MC) simulation model for the Leksell Gamma Knife (LGK) Perfexion (PFX) radiosurgery system.

METHOD

We previously established a source model for MC simulations of the LGK PFX for the purpose of the treatment planning system (TPS) dose verification and plan evaluation. To make practical and effective use of the model in clinic, several issues need to be addressed. First, thorough commissioning procedures are needed to ensure the validity of the model parameters, such as the source-to-focus (STF) distance, the source solid angle. Second, an efficient source particle sampling method is required to facilitate dose calculations for multitarget and multishot configurations in patient treatment plans. Third, inseparably, it is interesting to know the dose difference between the two GK TPS algorithms (TMR and convolution) and the MC method in extreme heterogeneous cases resulting from the inhomogeneous effect. We report our recent development in addressing these issues. Phantoms with the frame fiducials were manually created in the format of DICOM CT image to eliminate the uncertainties associated with scanner artifacts and image registration. The created homogeneous phantom was used to calibrate the model parameters to match the output factors with the manufacturer provided data, and the heterogeneous phantom with multilayer materials was used to study the inhomogeneous effect.

RESULTS

The agreement between the MC calculation and TPS was very good for the homogeneous spherical phantom. The difference of the full width at half maximum (FWHM) of the profiles was less than 1 mm except for the profile for 16 mm collimator along z-axis (less than 2 mm). For the extreme heterogeneous test case, it was shown that the TMR algorithm can overestimate the target dose by up to 22% using the measure of dose volume parameter D95. The agreement between the MC method and the TPS convolution method was better (within 3.6%) for the target near the center of phantom, however, discrepancy (up to 10.7%) existed for the target close to the skull. The difference between the two TPS dose algorithms was about 11%.

CONCLUSIONS

Considerable dose difference may result from the effect of heterogeneity, such as in the regions of the air cavities and bones. As the MC method has been extensively used in conventional external beams, it is worthwhile for further investigation in applying the MC method to accurate dose planning in the new GK PFX radiosurgery platform.

Modification and validation of an analytical source model for external beam radiotherapy Monte Carlo dose calculations

PURPOSE

A dose calculation tool, which combines the accuracy of the dose planning method (DPM) Monte Carlo code and the versatility of a practical analytical multisource model, which was previously reported has been improved and validated for the Varian 6 and 10 MV linear accelerators (linacs). The calculation tool can be used to calculate doses in advanced clinical application studies. One shortcoming of current clinical trials that report dose from patient plans is the lack of a standardized dose calculation methodology. Because commercial treatment planning systems (TPSs) have their own dose calculation algorithms and the clinical trial participant who uses these systems is responsible for commissioning the beam model, variation exists in the reported calculated dose distributions. Today's modern linac is manufactured to tight specifications so that variability within a linac model is quite low. The expectation is that a single dose calculation tool for a specific linac model can be used to accurately recalculate dose from patient plans that have been submitted to the clinical trial community from any institution. The calculation tool would provide for a more meaningful outcome analysis.

METHODS

The analytical source model was described by a primary point source, a secondary extra-focal source, and a contaminant electron source. Off-axis energy softening and fluence effects were also included. The additions of hyperbolic functions have been incorporated into the model to correct for the changes in output and in electron contamination with field size. A multileaf collimator (MLC) model is included to facilitate phantom and patient dose calculations. An offset to the MLC leaf positions was used to correct for the rudimentary assumed primary point source.

RESULTS

Dose calculations of the depth dose and profiles for field sizes 4 × 4 to 40 × 40 cm agree with measurement within 2% of the maximum dose or 2 mm distance to agreement (DTA) for 95% of the data points tested. The model was capable of predicting the depth of the maximum dose within 1 mm. Anthropomorphic phantom benchmark testing of modulated and patterned MLCs treatment plans showed agreement to measurement within 3% in target regions using thermoluminescent dosimeters (TLD). Using radiochromic film normalized to TLD, a gamma criteria of 3% of maximum dose and 2 mm DTA was applied with a pass rate of least 85% in the high dose, high gradient, and low dose regions. Finally, recalculations of patient plans using DPM showed good agreement relative to a commercial TPS when comparing dose volume histograms and 2D dose distributions.

CONCLUSIONS

A unique analytical source model coupled to the dose planning method Monte Carlo dose calculation code has been modified and validated using basic beam data and anthropomorphic phantom measurement. While this tool can be applied in general use for a particular linac model, specifically it was developed to provide a singular methodology to independently assess treatment plan dose distributions from those clinical institutions participating in National Cancer Institute trials.